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Abstract
Background: Early detection of the Acute Respiratory Distress Syndrome (ARDS) has the potential to improvethe prognosis
of critically ill patients admitted to the intensive care unit (ICU). However, no reliable biomarkers are currently available for
accurate early detection of ARDS in patients with predisposing conditions.
Objectives: This study examined risk factors and biomarkers for ARDS development and mortality in two prospective cohort
studies.
Methods: We examined clinical risk factors for ARDS in a cohort of 178 patients in Beijing, China who were admitted to the
ICU and were at high risk for ARDS. Identified biomarkers were then replicated in a second cohort of1,878 patients in
Boston, USA.
Results: Of 178 patients recruited from participating hospitals in Beijing, 75 developed ARDS. After multivariate adjustment,
sepsis (odds ratio [OR]:5.58, 95% CI: 1.70–18.3), pulmonary injury (OR: 3.22; 95% CI: 1.60–6.47), and thrombocytopenia,
defined as platelet count ,80610
3/mL, (OR: 2.67; 95% CI: 1.27–5.62)were significantly associated with increased risk of
developing ARDS. Thrombocytopenia was also associated with increased mortality in patients who developed ARDS
(adjusted hazard ratio [AHR]: 1.38, 95% CI: 1.07–1.57) but not in those who did not develop ARDS(AHR: 1.25, 95% CI: 0.96–
1.62). The presence of both thrombocytopenia and ARDS substantially increased 60-daymortality. Sensitivity analyses
showed that a platelet count of ,100610
3/mLin combination with ARDS provide the highest prognostic value for mortality.
These associations were replicated in the cohort of US patients.
Conclusions: This study of ICU patients in both China and US showed that thrombocytopenia is associated with an
increased risk of ARDS and platelet count in combination with ARDS had a high predictive value for patient mortality.
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Introduction
Acute respiratory distress syndrome (ARDS), the most severe
form of acute lung injury (ALI), is caused by several direct and
indirect insults to the lung,Life threatening and often lethal. ARDS
usually requires mechanical ventilation and admission to an
intensive care unit (ICU); ARDS is a major cause of ICU
morbidity and mortality worldwide [1]. Emerging viral diseases
such as severe acute respiratory syndrome (SARS) coronavirus,
H5N1 avian-origin influenza virus, and H1N1 swine-origin
influenza virus not only possess the potential for pandemic spread,
but also cause ARDS [2–4].These factors highlight the need for
additional research to improve understanding of the pathogenesis
of ARDS, with the ultimate goal of developing specific treatment
[5].
ARDS is associated with several clinical disorders, including
direct pulmonary injury from pneumonia and aspiration and
extra-pulmonary injury from sepsis, trauma, and multiple trans-
fusions [6]. Although low tidal volume ventilation, neuromuscular
blockers and prone positioning ventilation have advanced
treatments [7–9], there are currently no reliable predictive
markers for early detection of ARDS in predisposed individuals.
Nonetheless, many efforts have been mounted to identify biologic
markers, or biomarkers, for ARDS in critically ill patients,
including studies of pulmonary edema fluid, blood, and urine
[10–12]. Recent advances on the pathophysiological mechanisms
underlying ARDS have identified several clinical biomarkers to
PLOS ONE | www.plosone.org 1 April 2014 | Volume 9 | Issue 4 | e94124assess disease severity and outcome, including specific cytokines
and their receptors (IL-6, IL-8, soluble tumor factor receptors I
and II), products of epithelial and endothelial injury [receptor for
advanced glycation end-products (RAGE), surfactant protein D,
ICAM-1, and von Willebrand factor antigen], and markers of
altered coagulation (protein C and plasminogen activator inhib-
itor-1) [13]. However, no individual biomarker is strongly
associated with outcomes and thus cannot provide sufficient
discriminating power for either diagnosis or prognosis.
Biomarker discovery and validation requires patient samples
and must be combined with comprehensive clinical data collected
from properly designed trials in different populations. Given the
acute onset and rapid clinical progress of ARDS, a prospectively
enrolled cohort study in multicenter ICUs is suitable for more
complete and unbiased ARDS/ALI research [14]. Using a
protocol modified from a molecular epidemiology ARDS study
established in Boston, MA (Boston cohort) [14], we established a
multicenter ARDS cohort in Beijing, China (Beijing cohort) in
2009. The overarching objectives of establishing this prospective
cohort are to validate relevant biomarkers to ARDS, as well as
genetic polymorphisms, discovered in previous USA studies in
Chinese population, and discover new biomarkers of ARDS with a
comprehensive sampling protocol. In this report, we present initial
results on the clinical factors associated with ARDS development
and mortality in individuals with or at risk for ARDS. Associated
clinical factors were replicatedin the Boston cohort.
Methods
This study was approved by the institutional review board-
s(IRBs) of the Peking university third hospital, Beijing Friendship
Hospital, China-Japan Friendship Hospital, Beijing Chao-Yang
Hospital, and Harvard School of Public Health and a written
informed consent was obtained from each subject or an
appropriateproxy of the patient.
Study population
Four medical and surgical ICUs within four tertiary hospitals
participated in the study; hospitals covered the metropolitan area
of Beijing, China and included Peking University Third Hospital
in the northwest (16 beds), Beijing Friendship Hospital in the south
(16 beds), Beijing Chao-Yang Hospital in the east (14 beds), and
China-Japan Friendship Hospital in the northeast (10 beds).
As an international collaboration, we used a modified study
protocol for recruitment as previously described [14]. Briefly, we
screened each ICU admission for eligible subjects, which were
defined as critically ill patients with at least one predisposing
condition for ARDS: 1) sepsis; 2) septic shock; 3) trauma; 4)
pneumonia; 5) aspiration; 6) massive transfusion of packed red
blood cells (PRBC; defined as .8 PRBC units during the 24 hours
prior to admission); or 7) severe pancreatitis. To avoid interference
in biomarker research from certain clinical conditions, exclusion
criteria included:1) age ,18 years; 2) history of chronic lung
diseases, such as interstitial pulmonary fibrosis or bronchiolitis; 3)
history of pneumonectomy; 4) treatment with immunomodulating
therapy other than corticosteroids, such as granulocyte colony
stimulating factor, cyclophosphamide, cyclosporine, interferon, or
TNF-a antagonists; 5) presence of other immunodeficient condi-
tions, such as HIV infection, leukemia, or neutropenia (absolute
neutrophil count ,1000/ml); 6) history of solid or bone marrow
transplant other than autologous bone marrow transplant; and 7)
directive to withhold intubation. Sepsis and septic shock were
defined by the American College of Chest Physicians/Society of
Critical Care Medicine (ACCP/SCCM) Consensus Conference
[15].
After enrollment, subjects were followed daily for the develop-
ment of ARDS, as defined by the American-European Consensus
Committee (AECC) as follows [16]: a) evidence of hypoxemia with
Pao2/Fio2#200 mm Hg; b) evidence of bilateral infiltrates on
chest radiographs; and c) absence of left atrial hypertension with
pulmonary arterial occlusion pressure #18 mm Hg or no
congestive heart failure. Controls were identified as at-risk patients
who did not meet criteria for ARDS during the ICU stay and had
no prior history of ARDS. Infiltrates on chest radiographs were
defined as opacities that could not be explained completely by
pleural effusions, mass, body habitus, or collapse. Upper zone
redistribution and pulmonary vascular congestion were not
considered infiltrates. Two pulmonary and critical care physicians
interpreted daily chest radiographs; any disagreement went to a
third intensivist for arbitration. All physicians underwent a
consensus training session on the radiologic criteria for ARDS.
All were blinded to the clinical status of the patients.
Data and sample collection
We collected clinical data by chart review, including demo-
graphic information of age, gender, race, height, weight and
medical history of ARDS, diabetes, tobacco and alcohol abuse,
and liver disease. Baseline clinical information, worst vital signs,
and laboratory testing results in the first 24 hours of ICU
admission were collected for calculation of the Acute Physiological
and Chronic Health Evaluation (APACHE II) score for severity of
illness [17]. We also collected ventilatory parameters including the
requirement and mode of mechanical ventilation, PaO2/FiO2
ratio, positive end-expiratory pressure, tidal volume, and peak and
plateau pressures. All enrolled patients were followed until one of
the following situations occurred: hospital discharge, death, or 60
days after study entry. Starting in late 2006, based on finding from
ARDS network trials, Chinese ICUs universally adopted lower
tidal volume for mechanical ventilation [18].
Statistical analysis
Baseline characteristics were compared between groups with
Fisher’s exact test or chi-square test for dichotomous or categorical
variables and with Student’s t test or Mann–Whitney test for
continuous variables. For risk analysis of ARDS development, we
initially used a logistic regression model with a backward stepwise
elimination algorithm to select clinical risks or predictors from the
univariate analyses with p,0.1; the final logistic regression models
also included predictors from backward elimination. For mortality
analysis, we used the log-rank test as a univariate measure of
association and employed Cox proportional hazards models to
investigate each clinical variable’s effect on clinical outcome. We
used the time-dependent receiver operating characteristic (ROC)
method to determine the best cut-off value of thrombocytopenia in
the prediction of prognosis of critically ill patients by exploring the
area-under-the-curve (AUC) values at 60-day mortality, and
selected the maximal sumof sensitivity and specificity [19]. All
analyses were performed with the SAS statistical software package
(version 9.31, SAS Inc., Cary, NC), and p,0.05 was considered
statistically significant.
Results
Between July 2010 and April 2012, we recruited 178 patients
with at least one predisposing condition for ARDS from the
participating hospitals in Beijing, China. The majority of patients
were male (n=125, 70%) and the mean age was 63 years (median:
Thrombocytopenia and ARDS Mortality
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II score was 16 (interquartile range: 12–22) and median length of
time in the ICU was 10.5 days (interquartile range: 5–17 days).
Mechanical ventilation was used on 149 patients (84%) for a
median length of six days (interquartile range: 2–11 days). Thirty-
nine patients had diabetes, and one patient had chronic kidney
disease.
ARDS development
During hospitalization, 75 (41%) patients developed ARDS;a-
mong identified cases,31 (41%) and 70 (93%) of the 75 ARDS
patients were diagnosed within the first 24 and 72 hours of ICU
admission, respectively. There were no significant differences in
age, gender, smoking status, and initial APACHE II score between
ARDS patients and at-risk non-ARDS patients (Table 1). In
addition, the major physiological variables during the first
24 hours of ICU admission were comparable, except that patients
who developed ARDS had higher respiratory rates (p=0.025).
Although not significant, ARDS patients were in the ICU longer
(ARDS median=13 days; non-ARDS median=9 days; p=0.21)
and on mechanical ventilation longer (ARDS median=7 days;
non-ARDS median=5 days;p=0.53) than non-ARDS patients.
Low tidal volume (,7 ml/kg) was used in treating patients with
mechanical ventilation. Although patient specific data was not
available, protocolled low tidal volume ventilation was standard-
ized in study ICUs.
Among predisposing conditions for ARDS in all enrolled
patients, sepsis and/or septic shock (n=149, 83%) were the most
Table 1. Baseline characteristics of the Beijing cohort.
Non-ARDS (n=103) ARDS (n=75) p
Female, n (%) 34 (33.0) 19(25.3) 0.27
Age, median (range) 70(18–99) 67 (18–91) 0.32
Smoking history, n (%) 21 (20.4) 20 (26.7) 0.34
Baseline severity of illness (1
st 24 hours of ICU admission)
APACHE II, median(range)* 15 (4–39) 17 (6–35) 0.79
Systolic BP,,90 mmHg, n (%) 33 (32.0) 21 (28) 0.64
Heart rate,.100 beats/min, n (%) 82 (79.6) 57 (76) 0.84
Respiratory rate,.30 breaths/min, n (%) 27 (26.7) 31 (43.1) 0.03
Creatinine,.2.0 mg/L, n (%) 37 (35.9) 22 (29.3) 0.36
Bilirubin,.2.0 mg/dL, n (%) 35 (34.0) 21 (28) 0.23
Thrombocytopenia, #80610
9 platelets/L, n (%) 26 (25.2) 28 (37.3) 0.07
Albumin,,25 g/dL, n (%) 25 (61) 16 (39) 0.57
Arterial pH,,7.33, n (%) 35 (35) 28 (37.3) 0.74
Arterial pH,,7.22, n (%) 4 (3.9) 7 (9.3) 0.14
Comorbidities, n (%)
Diabetes 23 (22.3) 16 (21.3) 0.87
Predisposing conditions for ARDS, n (%)
Sepsis syndrome 80 (77.7) 69 (92) 0.01
Septic shock 47 (45.6) 31 (41.3) 0.57
Pneumonia 35 (34) 29 (38.7) 0.52
Pancreatitis 11 (10.7) 12 (16) 0.30
Trauma 3 (2.9) 3 (4) 0.70
Multiple transfusions 10 (9.7) 5 (6.7) 0.47
Aspiration 2 (1.9) 10 (13.3) 0.004
.1 risk for ARDS 38 (36.9) 51 (68) ,0.0001
Direct pulmonary injury vs. external pulmonary injury
{ 36 (35) 39 (52) 0.02
Clinical outcomes
60-day mortality, n (%) 38 (36.9) 31 (41.3) 0.55
Days in ICU, median (IQR) 8 (5–14) 11 (7–27) 0.21
Days on mechanical ventilation, median (IQR) 5 (2–10) 7 (3–14) 0.53
ARDS=acute respiratory distress syndrome; APACHE=Acute Physiology and Chronic Health Evaluation; ICU=intensive care unit; IQR=interquartile range.
*APACHE II score was calculated with all components within 24 hours of ICU admission.
{Pneumonia, aspiration, pulmonary contusions, or sepsis from lower pulmonary source were categorized as direct pulmonary injury; sepsis from an extrapulmonary
source, trauma without pulmonary contusions, and multiple transfusions were categorized as external pulmonary lung injury. Patients with both direct and external
pulmonary injuries were considered to have direct lung injury.
doi:10.1371/journal.pone.0094124.t001
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ARDS Non-ARDS All
Total Death
75%
survival p Total Death
75%
survival pp
n n (%) Day n n (%) Day
Gender 0.362 0.945 0.461
Male 56 25 (45) 29 69 25 (36) 38
Female 19 6 (32) 17 34 13 (38) 14
Age 0.053 0.023 0.004
Smoking status 0.745 0.24 0.321
Non-smoker 55 23 (42) 27 81 32 (40) 25
Smoker 20 8 (40) 17 21 5 (24) -
Diabetes 0.707 0.988 0.717
Non-diabetic 59 22 (37) 20 80 29 (36) 17
Diabetic 16 9 (56) 39 23 9 (39) 28
Baseline severity of illness (1st 24 hours of ICU admission)
APACHE II* 0.048 0.0002 ,0.0001
Systolic blood pressure 0.364 0.527 0.951
$90 mmHg 52 20 (38) 29 70 27 (39) 25
,90 mmHg 21 10 (48) 11 33 11 (33) 19
Heart rate 0.278 0.093 0.55
#100 beats/min 15 8 (53) 31 20 4 (20) 57
.100 beats/min 57 22 (39) 17 82 34 (41) 17
Respiratory rate 0.403 0.019 0.23
#30 breaths/min 41 18 (44) 20 74 23 (31) 45
.30 breaths/min 31 12 (39) 29 27 15 (56) 11
Creatinine 0.997 0.004 0.028
#2.0 mg/L 53 22 (42) 20 66 18 (27) 60
.2.0 mg/L 22 9 (41) 27 37 20 (54) 12
Bilirubin 0.895 0.296 0.45
#2.0 mg/dL 53 23 (43) 24 59 20 (34) 42
.2.0 mg/dL 21 8 (38) 11 35 14 (10) 11
Thrombocytopenia 0.022 0.436 0.024
Platelet .80610
9/L 46 15 (33) 34 77 27 (35) 19
Platelet #80610
9/L 28 16 (57) 9 26 11 (42) 21
Albumin 0.59 0.071 0.297
$25 g/dL 59 22 (37) 20 75 31 (41) 18
,25 g/dL 16 9 (56) 25 25 6 (24) -
Arterial pH 0.208 0.149 0.051
$7.33 47 16 (34) 31 67 21 (31) 42
,7.33 28 15 (54) 13 36 17 (47) 12
Predisposing conditions for ARDS
Sepsis 0.959 0.831 0.959
No sepsis 6 2 (33) 19 23 7 (30) 17
Sepsis 69 29 (42) 24 80 31 (39) 22
Septic shock 0.014 0.273 0.486
No septic shock 44 13 (29) 34 56 22 (39) 17
Septic shock 31 18 (58) 10 47 16 (34) 28
Pneumonia 0.382 0.001 0.002
No pneumonia 46 17 (37) 19 68 19 (28) 42
Thrombocytopenia and ARDS Mortality
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pancreatitis (n=23, 13%). Table 1 also shows the proportions of
patients who developed ARDS with each condition. Patients with
sepsis (p=0.01), aspiration (p=0.004), or multiple predisposing
conditions (p,0.0001) had significantly higher ARDS risk. Patients
with direct pulmonary injury were more likely to develop ARDS
than patients with extra pulmonary injury (p=0.02). From
multivariate modeling, sepsis [odds ratio (OR)=5.58; 95%
confidence intervals (CI)=1.70–18.26; p=0.005), direct pulmo-
nary injury (OR=3.22; 95% CI=1.60–6.47; p=0.001), and
thrombocytopenia (platelet count ,80610
3/mL) (OR=2.67; 95%
CI=1.27–5.62; p=0.005) [20] were associated with development
of ARDS.Respiratory rate (.30 breaths/min), aspiration, and .1
risks for ARDS were also evaluated in model selection but were
eliminated during model selection (not significant). APACHE II
score (removing age and gender components), age, and gender
were forced in as covariatesbut not significant in logistic regression
analyses. Known factors related to ARDS, including septic shock,
diabetes, and alcohol use, were also tested either by forcing as
covariates, individually or combined into the model, and did not
change the significant associations of sepsis, direct pulmonary
injury, and thrombocytopenia with the development of ARDS
(data not shown).Because drinking habits in China differ from
those in the U.S.,and it was difficult to develop a comparable
criterion for alcohol abuse, we did not including alcohol abuse as
risk factor in the analysis.
We further conducted a stratified analysis and found that
thrombocytopenia was significantly associated with ARDS in both
the Beijing cohort (univariate analysis, p=0.01) and the Boston
cohort (univariate analysis, p,0.0001) (Table S1), which has 851
ARDS and 1,027 non-ARDS patients recruited at Massachusetts
General Hospital in Boston, USA [21], in the subgroup patients
with septic shock, but not in non-septic shock subgroup (p=0.95
and p=0.15, respectively).
Some patients had already developed ARDS before ICU
admission, and this subgroup caseswas usually mixed with those
patients who were diagnosed ARDS during the first 24 hours of
ICU admission, together accounting for a total of 41% ARDS in
the Beijing cohort and 40% in the Boston cohort (340 of 851
identified cases). Since the thrombocytopenia was defined by the
lowest platelet counts during the first 24 hours of ICU admission
in these cohorts, some patients developed thrombocytopenia
before the onset of ARDS, who were difficult to be distinguished
within this subgroup ARDS, and could interfere with the finding
that thrombocytopenia was associated with development of
ARDS. We then performed a nested analysis on a clean subgroup
patients, by removing ARDS patients who were diagnosed during
the first 24 hours of ICU admission, and found that thrombocy-
topenia was still significantly associated with ARDS risk
(OR=4.04; 95% CI=1.41–11.59; p=0.009). Because of the
small sample size of the Beijing cohort, we further conducted the
sensitivity test in the Boston cohort in 411 ARDS cases and 1,027
non-ARDS patients after removing ARDS patients who were
Table 2. Cont.
ARDS Non-ARDS All
Total Death
75%
survival p Total Death
75%
survival pp
n n (%) Day n n (%) Day
Pneumonia 29 14 (48) 24 35 19 (54) 12
Pancreatitis 0.01 0.967 0.061
No pancreatitis 63 30 (48) 17 92 34 (37) 25
Pancreatitis 12 1 (8) - 11 4 (36) 8
Trauma 0.163 0.241 0.071
No trauma 72 31 (43) 20 100 38 (38) 19
Trauma 3 0 (0) - 3 0 (0) -
Multiple transfusions 0.629 0.365 0.311
No multiple
transfusions
70 29 (41) 24 93 36 (39) 19
Multiple transfusions 5 2 (40) 46 10 2 (20) -
Aspiration 0.92 0.434 0.856
No aspiration 65 27 (42) 24 101 38 (38) 19
Aspiration 10 4 (40) 7 2 0 (0) -
Pulmonary injury
{ 0.812 0.003 0.013
Direct pulmonary
injury
36 14 (39) 17 67 19 (28) 42
External pulmonary
injury
39 17 (44) 29 36 19 (53) 12
ARDS=acute respiratory distress syndrome; APACHE=Acute Physiology and Chronic Health Evaluation; ICU=intensive care unit.
*APACHE II score was calculated with all components within 24 hours of ICU admission;
{Pneumonia, aspiration, pulmonary contusions, or sepsis from lower pulmonary source were categorized as direct pulmonary injury; sepsis from an extrapulmonary
source, trauma without pulmonary contusions, and multiple transfusions were categorized as external pulmonary lung injury. Patients with both direct and external
pulmonary injuries were considered to have direct lung injury.
doi:10.1371/journal.pone.0094124.t002
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cytopenia were significantly associated with development of ARDS
(OR=1.85; 95% CI=1.33–2.58; p=0.0003), with the adjustment
of APACHE II score (removing age and gender components), age,
gender, sepsis, trauma, blood transfusion, direct pulmonary injury,
and alcohol use, which was consistent with the results of entire
sample set (OR=1.71; 95% CI=1.27–2.31; p=0.0005).
Mortality
The 60-day mortality rate for all patients was 39%, and the
development of ARDS did not increase mortality risk (Table 1).
Among predisposing conditions for ARDS, septic shock was
associated with increased mortality (p=0.014), but pancreatitis
was associated with decreased mortality (p=0.01) in ARDS
patients (Table 2). In contrast, pneumonia (p=0.002) and external
pulmonary injury (p=0.013) had higher mortality rates in non-
ARDS patients.
Univariate examination of demographic characteristics and
physiologic variables in the first 24 hours of ICU admission
revealed that higher APACHE II scores and older age were
associated with increased mortality for both ARDS and non-
ARDS patients (Table 2). Thrombocytopenia was significantly
associated with mortalityof ARDS (p=0.022) but not non-ARDS
(p=0.436) patients. In contrast, high serum creatinine levels
(.2.0 mg/L) were associated with higher mortality in non-ARDS
(p=0.004) but not ARDS (p=0.997) patients. There were no
statistically significant differences between survivors and non-
survivors for gender, history of diabetes, and tobacco or alcohol
use.
In multivariate analysis, APACHE II score was consistently
associated with increased mortality in ARDS, non-ARDS, and all
patients (Table 3). Thrombocytopenia was a mortality covariate
for ARDS and all patients, but not for non-ARDS patients
(Table 3). When replaced with coagulation points of the
Sequential Organ Failure Assessment score (SOFA), thrombocy-
topenia remained associated with higher mortality in ARDS
[adjusted hazard ratio (AHR)=1.38; 95% CI=1.07–1.57;
p=0.04]and all patients (AHR=1.30; 95% CI=1.07–1.57;
p=0.008), but not in non-ARDS patients (AHR=1.25; 95%
CI=0.96–1.62; p=0.09). To replicate our findings, we analyzed
data from the Boston cohort. Although univariate analyses
identified more physiologic variables in the first 24 hours of ICU
admission and ARDS-predisposing conditions significantly associ-
ated with mortality (Table S1 and S2), multivariate analyses
identified APACHE II score and thrombocytopenia as major risk
factors for mortality in ARDS, non-ARDS, and all patients
(Table 3). We also found similar results when thrombocytopenia
was replaced with coagulation points of the SOFA score (data not
shown).
We further investigated the interaction between thrombocyto-
penia and ARDS on mortality of all patients by creating a
combined covariate of the Boston and Beijing cohorts. In both
univariate (Figure 1) and multivariate (Figure 2) analyses, the
combination of thrombocytopenia and ARDS had consistently
higher patient mortality.
Taking advantage of the size of the Boston cohort, we
conducted a sensitivity analysis to determine the optimal platelet
count for prognosis.With adjustmentsfor age, gender, APACHE II
score, and sepsis, a platelet count of 104610
3/mLhad the maximal
ROC value (AUC=0.661; sensitivity=0.508; specificity=0.739;
p=0.0007). A sensitivity analysis confirmed a platelet count of
100610
3/mL by considering a series of stepped (10610
3/mL)cut-
Table 3. Multivariable analysis of mortality predictors in Beijing and Boston cohorts.
Beijing cohort Boston cohort
Covariate AHR (95% CI) p AHR (95% CI) p
ARDS N=75 N=851
APACHE II 1.05 (1.00–1.10) 0.04 1.05 (1.03–1.08) ,0.0001
Thrombocytopenia 2.20 (1.09–4.46) 0.03 1.69 (1.23–2.32) 0.001
Age NS 1.03 (1.02–1.04) ,0.0001
Bilirubin, .2.0 mg/dL NS 1.45 (1.08–1.95) 0.01
Non-ARDS N=103 N=1027
APACHE II 1.08 (1.04–1.12) 0.0002 1.07 (1.04–1.10) ,0.0001
Thrombocytopenia 1.29 (0.64–2.59) 0.48 1.63 (1.14–2.34) 0.008
Pneumonia 2.04 (1.02–4.09) 0.04 NS
Age NS 1.03 (1.02–1.04) ,0.0001
Aspiration NS 1.79 (1.18–2.73) 0.006
All patients N=178 N=1878
APACHE II 1.07 (1.03–1.10) ,0.0001 1.07 (1.05–1.08) ,0.0001
Thrombocytopenia 1.89 (1.16–3.08) 0.01 1.97 (1.56–2.48) ,0.0001
Pneumonia 2.01 (1.24–3.26) 0.005 NS
Age NS 1.02 (1.02–1.03) ,0.0001
Trauma NS 0.09 (0.01–0.67) 0.02
Direct pulmonary injury NS 1.36 (1.12–1.65) 0.002
ARDS=acute respiratory distress syndrome; APACHE=Acute Physiology and Chronic Health Evaluation; AHR=adjusted hazard ratio; CI=confidence intervals; NS=not
selected in multivariate modeling.
doi:10.1371/journal.pone.0094124.t003
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3/mLto 150610
3/mL(Table 4).The Beijing
cohort replicated this value (platelet counts,100610
3/mL& non-
ARDS: AHR=2.42; 95% CI=1.25–4.68; p=0.009; platelet
counts$100610
3/mL& ARDS: AHR=1.25; 95% CI=0.61–
2.56; p=0.551; platelet counts,100610
3/mL& ARDS:
AHR=3.03; 95% CI=1.55–5.93; p=0.001).
Discussion
This prospective multicenter cohort was established using a
modified protocol originally implemented in the Boston cohort
[14]. Among at-risk ICU patients, 41% developed ARDS during
ICU admission, and a majority of those patients (93%) developed
ARDS within the first 72 hours of admission. These observations
are consistent with previous reports in the mostly-Caucasian
Boston cohort [14]. Moreover, the profiles of baseline physiologic
variables and the major clinical risk factors between ARDS and at-
risk non-ARDS patients are similar to previous reports from
Chinese [22,23] andAmerican [14] ICUs.Furthermore, the
observation of high baseline respiratory rate (.30 breaths/min)
associated with ARDS cases was consistent withthe findings from
several previous studies [24–26].
In this cohort, in addition to sepsis and direct pulmonary injury,
thrombocytopenia was associated with the development of
ARDS.Enhanced platelet activation resulting in platelet deposition
within the damaged pulmonary microvasculature has been
supported by several clinical and preclinical studies of ALI
[27,28], and thrombocytopenia has been reported as a key feature
of SARS [29]. In the Boston cohort, thrombocytopenia (named
hematologic failure) was also identified as a risk factor for ARDS
in multivariate analysis [14]. In another cohort of ALI in
Rochester, Minnesota (Mayo Clinic), however, researchers did
not observe significant difference of platelet count between ALI
and non-ALI patients with septic shock [18]. Since the Rochester
cohort only focuses on a subgroup ICU patients with septic shock,
our stratified analysis revealed that thrombocytopenia was
Figure 1. Survival curves of the effects of thrombocytopenia and acute respiratory distress syndrome (ARDS) on 60-day mortality.
Univariate survival analyses show Kaplan-Meier curves of thrombocytopenia (platelet count ,80610
3/mL) and ARDS development on 60-day
mortality among critically ill patients at-risk for ARDS in the Beijing cohort (upper panel, p=0.05) and the Boston cohort (lower panel, p,0.0001).
Blue: non-thrombocytopenia & non-ARDS; red: thrombocytopenia & non-ARDS; green: non-thrombocytopenia & ARDS; orange: thrombocytopenia &
ARDS.
doi:10.1371/journal.pone.0094124.g001
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the Boston cohort in the subgroup patients with septic shock, but
not in non-septic shock subgroup. The different results might be
explained by that the Beijing cohort and the Boston cohort focused
on ARDS, which is the most severe form of ALI.
A major finding of this study is the association ofthrombocy-
topenia with increased ARDS mortality. Extensive evidence
Figure 2. Adjusted hazard ratios of thrombocytopenia and acute respiratory distress syndrome (ARDS) on 60-day mortality.
Multivariate analyses show adjusted hazard ratios (95% confidence intervals) of thrombocytopenia(platelet count ,80610
3/mL) and ARDS
development on 60-day mortality among critically ill patients at-risk for ARDS in the Beijing cohort (red) and the Boston cohort (blue), adjusted by
APACHE II.
doi:10.1371/journal.pone.0094124.g002
Table 4. Sensitivity analysis of combined effects of thrombocytopenia and ARDS
{.
cutoff point for
platelet count* Platelet count ,cutoff & Non-ARDS Platelet count $cutoff & ARDS Platelet count ,cutoff & ARDS
AHR
{ p AHR
{ p AHR
{ p
50 1.39(0.81,2.36) 0.2286 1.79(1.47,2.18) 6.50E-09 3.62(2.45,5.34) 8.80E-11
60 1.36(0.84,2.19) 0.2107 1.74(1.42,2.13) 6.30E-08 3.91(2.78,5.51) 5.40E-15
70 1.37(0.90,2.07) 0.1407 1.76(1.43,2.15) 5.60E-08 3.43(2.47,4.76) 1.80E-13
80 1.51(1.04,2.19) 0.0308 1.75(1.42,2.16) 1.50E-07 3.40(2.51,4.60) 2.10E-15
90 1.44(1.01,2.05) 0.0459 1.68(1.36,2.08) 1.90E-06 3.66(2.74,4.87) ,1E-16
100 1.42(1.02,1.97) 0.0356 1.68(1.35,2.09) 3.00E-06 3.47(2.62,4.59) ,1E-16
110 1.35(0.99,1.85) 0.0587 1.68(1.34,2.09) 5.20E-06 3.19(2.42,4.19) 1.10E-16
120 1.39(1.03,1.88) 0.0316 1.69(1.35,2.12) 5.00E-06 3.12(2.38,4.09) 2.20E-16
130 1.33(0.99,1.77) 0.0543 1.70(1.35,2.15) 7.20E-06 2.84(2.18,3.69) 1.20E-14
140 1.25(0.94,1.65) 0.1213 1.73(1.36,2.19) 5.80E-06 2.58(1.99,3.36) 1.60E-12
150 1.27(0.97,1.67) 0.0856 1.73(1.36,2.21) 1.00E-05 2.58(1.99,3.34) 8.80E-13
ARDS=acute respiratory distress syndrome; AHR=adjusted hazard ratio.
*Each line represents a multivariate cox regression with adjustment of age, gender, APACHII score, and sepsis; Platelet count (610
3/mL) was dichotomized by cutoff
point;
{AHR was estimated by comparison with non-thrombocytopenia/non-ARDS group.
doi:10.1371/journal.pone.0094124.t004
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associated with increased ICU morbidity and mortality [30].
Although thrombocytopenia is a well-established prognostic
marker for mortality in patients with sepsis and septic shock
[31], which are risk factors for developing ARDS, thrombocyto-
penia has been inconsistently associated with ARDS mortality in
two previous studies with small patient series representing non-
contemporary treatment eras [32,33]. Besides APACHE II score,
thrombocytopenia was the only risk factor for ARDS mortality
identified in the Beijing cohort. Further, this association was
replicatedwitha larger population and different ethnicities in the
Boston cohort. These results provide strong evidence that
thrombocytopenia is a prognostic marker for ARDS mortality.
In both Beijing and Boston cohorts, the combination of
thrombocytopenia and ARDS further increased risk of 60-day
mortality among critically ill patients. Thrombocytopenia in ICU
patients is caused by multiple factors [34] and is considered a
marker of illness severity with Multiple Organ Dysfunction Scores
(MODS), SimplifiedAcute Physiology Scores (SAPS), and
APACHE scores.Sepsis alone can cause moderate thrombocyto-
penia, as maladaptive platelet-neutrophil interactionssignificantly
increase platelet activation and aggregation, as well as tissue injury
[35]. The lung epithelium is central to both the pathogenesis and
resolution of ARDS, and intra-alveolar coagulation changes (e.g.,
platelet-fibrin deposition and pulmonary vascular thrombi) are
hallmarks of pathologic changes in ARDS [36]. Thus, thrombo-
cytopenia likely contributes to the development of ARDS; in
return, the coexistence of ARDS may aggravate thrombocytope-
nia to increase mortality of critically ill patients.
We used the same platelet count criterion from the Boston
cohort (,80610
3/mL)to define thrombocytopenia [14]. Although
platelet counts are routinely measured daily in the ICU, the
epidemiology of thrombocytopenia in critically ill patients has not
been well studied. Further, illness severity scoring systems
inconsistently consider platelet count;for example, the SOFA
score incorporates platelet count, whereas the APACHE score
does not. Different platelet count thresholds have been used in
epidemiological studies for the prevalence, incidence, risk factors,
and consequences of thrombocytopenia among critically ill
patients [37]. Currently, the RAND/UCLA Appropriateness
Methodrecommends a platelet count threshold of ,100610
3/
mL, or a .30% decrease in platelet counts, for epidemiological
research of thrombocytopenia [20]. Taking advantage of a large
patient population in the Boston cohort, we conducted a sensitivity
analysis and determined that platelet count (,100610
3/mL) was a
significant prognostic marker for ARDS. We further replicated this
cut-point value in the Beijing cohort.
There were some differences between the Beijing and Boston
cohorts. When evaluated individually, there were different
association profiles for thrombocytopenia and ARDS with
mortality of all patients with at least one risk factor for ARDS.
Thrombocytopenia was significantly associated with higher
mortality in the Beijing cohort, but not the Boston cohort.
Conversely, ARDSwas associated with higher mortality in the
Boston cohort, but not the Beijing cohort. It is unexpected that
ARDS did not increase mortality in the Beijing cohort, and. it is
counter-intuitive that in the univariate analysis thrombocytopenia
would be associated with increased mortality in the ARDS group
but not in the non-ARDS group given that thrombocytopenia is a
marker of severity of illness in critical care populations generally.
However, the raw numbers were in the direction of higher
mortality with lower platelets in the non-ARDS group, these
findings could be explained by the limitation of multiple subgroup
analysis in a relatively small dataset. Moreover, for several known
risk factors or comorbidities of ARDS [14,24–26], such as septic
shock, pneumonia, pancreatitis, trauma, multiple transfusions, and
diabetes, we did not observe significant different between ARDS
and non-ARDS patients in the Beijing cohort. Due to the relative
scarcityand high cost of medical resources to the general Chinese
population, the participating hospital ICUs in the Beijing
cohortmay have admitted more severely ill patients, resulting in
less difference in illness severity between ARDS and non-ARDS
patients. Accordingly, although most physiologic variables of the
first 24 hours of ICU admission, including APACHE score, were
comparable between ARDS and non-ARDS Beijing cohort
patients, thrombocytopenia (platelet counts ,80610
3/mL) was
more common in the Beijing cohort than the Boston cohort
(30.3% vs. 13.9%, respectively; p,0.0001). It is also possible that
different ethnicities account for the observed differencesbetween
cohorts.
Based on the Boston cohort, our study protocol was modified by
the inclusion of severe pancreatitis as a predisposing condition for
ARDS. Severe pancreatitis is a well-established risk factor for the
development of ARDS [38] and is frequently observed in critically
ill patients in China. In the Beijing cohort, we identified 23
(12.9%) cases of severe pancreatitis, similar to a previous report of
15.6% in a large Chinese ICU survey [39]. About 52% of severe
pancreatitis cases eventually developed ARDS during ICU
admission. Severe pancreatitis was not associated with ARDS
risk, but was associated with lower mortality. However, the Beijing
study is limited by a small sample size. With the patients’
enrollment keeps, we will further evaluate severe pancreatitis as a
clinically important factor in the development and outcome of
ARDS.
Conclusion
This study describes the successful establishment of a prospec-
tive, multicenter cohort study of critically ill patients at-risk for
ARDS in Beijing, China. Initial characterization of the clinical
factors associated with ARDS risk and mortality revealed an
association between thrombocytopenia and ARDS mortality. We
replicated these findings in the larger and more diverse Boston
cohort, suggesting that the Beijing cohort can provide compre-
hensive data and samples to identify biomarkers for the early
diagnosis, prognosis, and treatment of ARDS.
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